Search

Ovid therapeutics Inc

Geschlossen

BrancheGesundheitswesen

2.61 0.38

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

2.43

Max

2.64

Schlüsselkennzahlen

By Trading Economics

Einkommen

-27M

-17M

EPS

-0.12

Gewinnspanne

-2,366.017

Angestellte

23

EBITDA

-4.7M

-17M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+139.15% upside

Dividenden

By Acuity

Nächstes Ergebnis

19. Aug. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

6.2M

489M

Vorheriger Eröffnungskurs

2.23

Vorheriger Schlusskurs

2.61

Nachrichtenstimmung

By Acuity

77%

23%

309 / 340 Ranking in Healthcare

Ovid therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

12. Aug. 2026, 19:46 UTC

Ovid Therapeutics Inc shares are higher, supported by positive sentiment from a recent inflation report, despite earlier declines in the session.

7. Aug. 2026, 19:26 UTC

Ovid Therapeutics Inc shares are lower today amid broader market dynamics. The stock briefly peaked earlier in the session before declining.

6. Aug. 2026, 22:51 UTC

Ovid Therapeutics Inc. shares are lower in after-market trading, declining since Thursday's close despite remaining above its 20-day moving average.

5. Aug. 2026, 21:03 UTC

Ovid Therapeutics Inc shares are higher in after-market hours, continuing a positive trend from four consecutive days of gains. No specific news was identified.

4. Aug. 2026, 23:01 UTC

Ovid Therapeutics Inc shares are lower in after-market trading, with no specific news identified to explain the decline since Tuesday's close.

3. Aug. 2026, 19:11 UTC

News

Ovid Therapeutics shares are higher as Oppenheimer raises the price target to $9.00 from $7.00, maintaining an Outperform rating.

31. Juli 2026, 20:02 UTC

Ovid Therapeutics Inc shares are lower today amid rising Treasury yields and crude oil prices, contributing to broader inflation concerns affecting the biotechnology sector.

27. Juli 2026, 20:07 UTC

Ovid Therapeutics Inc shares are higher during Monday's session, following a cumulative gain since Friday. The stock pulled back from earlier session highs.

22. Juli 2026, 18:46 UTC

Ovid Therapeutics Inc shares are lower amid broader market volatility linked to rising crude oil prices and geopolitical tensions, with no specific news identified.

20. Juli 2026, 19:36 UTC

Ovid Therapeutics Inc shares are lower today, continuing a trend of declines amid broader market pressure from geopolitical tensions and rising oil prices.

Peer-Vergleich

Kursveränderung

Ovid therapeutics Inc Prognose

Kursziel

By TipRanks

139.15% Vorteil

12-Monats-Prognose

Durchschnitt 6.17 USD  139.15%

Hoch 9 USD

Tief 4 USD

Basierend auf 6 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Ovid therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

6 ratings

6

Buy

0

Halten

0

Sell

Stimmung

By Acuity

309 / 340 Ranking in Gesundheitswesen

Nachrichtenstimmung

Sehr starke bärische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Ovid therapeutics Inc

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
help-icon Live chat